Core Viewpoint - Huajian Medical has successfully secured a multi-billion yuan revolving loan for its subsidiary, demonstrating recognition of its operational capabilities and international capital's confidence in its future strategy [1] Group 1: Loan Acquisition - The loan was led by East Asia Bank's Shanghai branch, with participation from seven financial institutions, highlighting its significance in a tightening credit environment [1] - The loan approval is seen as a vote of confidence in Huajian Medical's development blueprint [22] Group 2: Stock Market Activity - Huajian Medical's stock price surged by 75% from July 14 to July 21, reaching a historical high of 4.66 HKD [5][15] - The company executed three high-priced stock buybacks from July 23 to July 28, spending over 6.13 million HKD, indicating management's confidence in the company's future [17][22] Group 3: Regulatory Environment - The Hong Kong Stablecoin Regulation will take effect on August 1, marking a significant regulatory shift in the global financial landscape [6] - The Hong Kong Monetary Authority (HKMA) has set high standards for stablecoin issuance, with only a few licenses expected to be granted initially [6][7] Group 4: Strategic Initiatives - Huajian Medical announced plans to establish a Web3 exchange focused on medical innovation assets and to issue a corresponding stablecoin, IVDD [8][9] - The company is pursuing stablecoin licenses in both the U.S. and Hong Kong, aiming to become the first medical technology firm to obtain such licenses in both markets [14] Group 5: Market Potential - The global market for Real World Asset (RWA) tokenization is projected to grow significantly, with estimates reaching 16.1 trillion USD by 2030 [24] - The stablecoin market is also expanding rapidly, with a total market cap of 263.6 billion USD, surpassing traditional payment systems [25] Group 6: Future Outlook - Huajian Medical's dual strategy of compliance in Hong Kong and aggressive expansion in the U.S. positions it uniquely in the market [26] - The company's innovative approach could potentially lead to a significant increase in market capitalization, with the possibility of reaching a valuation in the hundreds of billions [25][26]

Group 1 - The core viewpoint of the article highlights the strategic moves by Huajian Medical, including the successful fundraising of a multi-billion RMB sustainable development-linked revolving loan and the launch of a Web3 exchange ecosystem for medical innovation drugs [1][2][3] - The revolving loan, led by East Asia Bank and supported by several international financial institutions, provides Huajian Medical with a flexible and ample medium to long-term funding pool, enhancing its capital structure and enabling it to seize industry growth opportunities [2][3] - Huajian Medical's stock price surged by 75% from July 14 to July 21, reaching a historical peak of 4.66 HKD, reflecting strong market sentiment and confidence in the company's future prospects [1][3] Group 2 - The management's decision to repurchase shares at high prices, following the stock's peak, signals confidence in the company's strategic direction and future growth [4][5] - The company has initiated a plan to establish a Web3 exchange named "IVDNewCo Exchange," which aims to integrate medical innovation drug assets with blockchain technology, potentially revolutionizing traditional pharmaceutical financing [5][6] - The proposed ecosystem includes a tokenization platform for real-world assets (RWA), a decentralized exchange for 24/7 global trading, and a stablecoin (IVDD) for transactions within the ecosystem [6][8] Group 3 - The global RWA market is projected to grow significantly, reaching 16.1 trillion USD by 2030, indicating a favorable environment for Huajian Medical's tokenization strategy [8][9] - The stablecoin market is also expanding, with a total market cap of 263.6 billion USD, suggesting a growing acceptance of new financial infrastructures [8][9] - Regulatory developments, such as the upcoming Hong Kong Stablecoin Regulation, are expected to facilitate Huajian Medical's initiatives in the Web3 space, enhancing investor confidence [8][9]

Group 1 - The core viewpoint of the news is that Huajian Medical has successfully raised a multi-billion RMB sustainable development-linked revolving syndicated loan, which reflects the confidence of financial institutions in the company's future prospects and strategic initiatives [1][2][3] - The loan, led by East Asia Bank (China) and involving several international and regional financial institutions, provides Huajian Medical with a flexible and ample medium to long-term funding pool, enhancing its capital structure and enabling it to seize industry growth opportunities [2] - The company's stock price surged by 75% from July 14 to July 21, reaching a historical peak of 4.66 HKD, indicating strong market sentiment and investor confidence in its strategic direction [1][3] Group 2 - Huajian Medical's management demonstrated confidence by repurchasing shares at high prices after the stock reached historical highs, signaling their belief in the company's strategic future [4] - The company executed multiple stock buybacks between July 23 and July 28, spending over 6.13 million HKD, which reflects a strong endorsement of its "Web3 + innovative drug" strategy [4] - The establishment of a wholly-owned subsidiary in the U.S. and the initiation of stablecoin license applications further support the company's strategic ambitions [4] Group 3 - Huajian Medical aims to revolutionize the medical asset landscape by creating the "IVDNewCo Exchange," a Web3 ecosystem that integrates innovative drug assets with blockchain technology [5][6] - The proposed ecosystem includes a tokenization platform for real-world assets (RWA), a decentralized exchange for 24/7 global trading, and the IVDD stablecoin as a universal payment medium [6] - The strategy addresses the traditional pharmaceutical development model's pain points, allowing early-stage investors to share in the success of clinical trials through tokenized assets [6] Group 4 - The global RWA market is projected to grow significantly, reaching 16.1 trillion USD by 2030, indicating a favorable environment for Huajian Medical's tokenization strategy [8] - The stablecoin market is also expanding, with a total market cap of 263.6 billion USD, highlighting the potential for new financial infrastructure [8] - Regulatory developments, such as the upcoming Hong Kong Stablecoin Regulation, are expected to facilitate Huajian Medical's initiatives in the crypto-financial space [8] Group 5 - The market's response to Huajian Medical's initiatives is mixed, with strong stock performance indicating investor willingness to pay a premium for the "Web3 + innovative drug" narrative, while also reflecting concerns about the volatility and speculative nature of the market [9] - If successful, Huajian Medical's Web3 ecosystem could open new financing channels for medical assets, reducing investment barriers and enhancing liquidity in the traditionally closed innovative drug development space [9] - The combination of the syndicated loan, rising stock prices, and share buybacks represents a strong vote of confidence in Huajian Medical's disruptive experiment in the healthcare sector [9]

Core Viewpoint - The company, Huajian Medical (01931), announced a sustainable development-linked syndicated loan agreement for its subsidiary, Weishida Medical Equipment (Shanghai) Co., Ltd., which will provide a significant amount of revolving loans, reflecting strong market response and recognition from financial institutions [1] Group 1: Loan Agreement Details - The loan agreement was established on July 10, 2025, with a total amount reaching several hundred million RMB [1] - The repayment period for the loan is set at 12 months from the date of the first drawdown [1] - The syndicate is led by East Asia Bank (China) Co., Ltd. Shanghai Branch, with participation from several other banks including Sumitomo Mitsui Banking Corporation (China) Co., Ltd. and others [1] Group 2: Financial Implications - The revolving credit facility allows for repeated drawdowns during the drawdown period, providing Weishida with a flexible and ample medium to long-term funding pool [1] - The approval of this syndicated loan indicates a strong market response and highlights the recognition of Weishida's robust operations and sustainable development strategy by international and regional financial institutions [1]

Core Viewpoint - The announcement highlights the successful establishment of a sustainable development-linked syndicated loan agreement by the company’s subsidiary, which reflects strong confidence from financial institutions in the company's creditworthiness and sustainable growth prospects [1] Group 1: Loan Agreement Details - The subsidiary, 威士达医疗设备(上海)有限公司, has secured a revolving loan amounting to several hundred million RMB, with a repayment period of 12 months from the first drawdown [1] - The successful fundraising of this syndicated loan demonstrates the financial institutions' recognition of the group's market leadership and robust financial performance through rigorous due diligence [1] Group 2: Financial Implications - The large revolving loan will provide significant support for 威士达's liquidity management and business expansion, while also creating favorable conditions for the group's future financing needs [1] - The board anticipates that the successful execution of the loan agreement will enhance market confidence in the group and create long-term value for shareholders [1] - Following the signing and implementation of the loan agreement, the group expects to increase its financial flexibility and improve its financial condition, utilizing the funds for general working capital [1]

IVD Medical Holding Limited 華檢醫療控股有限公司 （於 開 曼 群 島 註 冊 成 立 之 有 限 公 司） （股 份 代 號：1931） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 自願性公告 威 士 達 醫 療 設 備（上 海）有 限 公 司 成 功 完 成 中 長 期 可持續發展掛鈎循環銀團貸款募集 本 公 告 乃 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」） 自 願 作 出，旨 在 向 本 公 司 股 東（「股 東」）及 潛 在 投 資 者 提 供 本 集 團 最 近 發 展 的 最 新 資 料。 本 公 司 董 事 會（「董事會」）謹 此 宣 佈，於 二 零 二 五 年 七 月 十 日，本 公 司 子 公 司 威 士 達 醫 療 設 備（上 海）有 限 公 司（「威士達」）（作 為 借 款 人）訂 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 重新提交 公司名稱： 華檢醫療控股有限公司 呈交日期： 2025年7月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01931 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 華檢醫療控股有限公司 呈交日期： 2025年7月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01931 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存 ...

注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 证券时报•数据宝统计显示，7月25日有17家香港上市公司进行了股份回购，合计回购985.07万股，回购 金额2306.22万港元。 百胜中国回购数量1.67万股，回购金额626.79万港元，回购最高价为382.800港元，最低价为373.600港 元，年内累计回购金额9.81亿港元；华检医疗回购数量141.40万股，回购金额507.63万港元，回购最高 价为3.590港元，年内累计回购金额1442.59万港元；蒙牛乳业回购数量20.00万股，回购金额343.33万港 元，回购最高价为17.280港元，最低价为17.020港元，年内累计回购金额2.45亿港元。 7月25日港股公司回购一览 | | | | | | | 年内累计 | | --- | --- | --- | --- | --- | --- | --- | | 代码 | 简称 | 回购股数 | 回购金额 | 回购最高价 | 回购最低价 | 回购金额 | | | | （万股） | （万港元） | （港元） | （港元） | | | | | | | | | （万港元） | | 09987 | 百 ...

Group 1 - The article reports on share buybacks conducted by various companies on July 25, 2025, with Yum China (09987) having the largest buyback amount of 6.2679 million yuan for 16,700 shares [1][2] - The total number of shares repurchased by Yum China in the year reached 3.2541 million, accounting for 0.870% of its total share capital [2] - Other notable companies involved in buybacks include Huajian Medical (01931) with 1.414 million shares repurchased for 5.0763 million yuan, and Mengniu Dairy (02319) with 200,000 shares for 3.4333 million yuan [2] Group 2 - The buyback activities reflect a strategic move by companies to enhance shareholder value and signal confidence in their financial health [1] - The buyback amounts and share counts for other companies include Xinyi International (00732) with 2.644 million shares for 3.2257 million yuan, and Beike-W (02423) with 462,600 shares for 3 million yuan [2] - The data indicates a diverse range of companies participating in buybacks, suggesting a broader trend in the market towards returning capital to shareholders [1][2]